Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development
of RNAi therapeutics, today announced that the first patient has been
dosed in a global Phase 1b/2 clinical trial of DCR-MYC, an
investigational Dicer substrate short interfering RNA (DsiRNA)
therapeutic, in patients with advanced hepatocellular carcinoma (HCC).
This new trial expands the development program for DCR-MYC, which is
also being studied in a Phase 1 clinical trial in patients with solid
tumors and hematological malignancies.
for Dicerna Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Clinical Trial of DCR-MYC, an Investigational RNAi Therapeutic Targeting the MYC Oncogene, in Patients with Advanced Hepatocellular Carcinoma investment picks